Similarly, a study of patients undergoing anti-TB treatment showed, compared to the baseline, a significant reduction in serum SAA1 level after the intensive phase of therapy (the first 2 months after treatment initiation), suggesting that SAA1 may also serve as a potential biomarker for monitoring treatment efficacy (67). This evidence concerns the gene SAA1 and tuberculosis.